As of March 15, 2023, Seychelles was the African country with the highest coronavirus (COVID-19) vaccination rate, with around 205 doses administered per 100 individuals. Mauritius and Rwanda followed with 201 and 190 doses per 100 people, respectively. Ranking fourth, Morocco had a vaccination rate of approximately 148 doses per 100 people, registering the third-highest number of inoculations after Egypt and Nigeria. In South Africa, the most affected country on the continent, the vaccination rate instead reached around 64 per 100 population.

How did Africa obtain the vaccines?

Vaccines in Africa were obtained in different ways. African nations both purchased new doses and received them from other countries. At the beginning of the vaccination campaigns, donations came from all over the world, such as China, the United Arab Emirates, India, and Russia. The United Nations-led COVAX initiative provided Oxford/AstraZeneca and Pfizer/BioNTech doses to several African countries. Within this program, the continent received nearly 270 million doses as of January 2022. Moreover, the vaccination campaign has also been an occasion for intra-African solidarity. Senegal has, for instance, donated vaccines to the Gambia, while in January 2021, Algeria announced that it would have shared its supply with Tunisia.

COVID-19 impact on the African economy

The spread of COVID-19 negatively affected socio-economic growth in Africa, with the continent’s Gross Domestic Product (GDP) contracting significantly in 2020. Specifically, Southern Africa experienced the sharpest decline, at minus six percent, followed by North Africa at minus 1.7 percent. Most of Africa’s key economic sectors were hit by the pandemic. The drop in global oil prices led to a crisis in the oil and gas sector. Nigeria, the continent’s leading oil-exporting country, witnessed a considerable decrease in crude oil trade in 2020. Moreover, the shrinking number of international tourist arrivals determined a loss of over 12 million jobs in Africa’s travel and tourism sector. Society has also been substantially affected by COVID-19 on the poorest continent in the world, and the number of people living in extreme poverty was estimated to increase by around 30 million in 2020.

The number of COVID-19 vaccination doses administered per 100 people in South Africa rose to 65 as of Oct 27 2023. This dataset includes a chart with historical data for South Africa Coronavirus Vaccination Rate.

As of November 22, 2021, around 41 percent of the adult population in South Africa had already been fully vaccinated against the coronavirus (COVID-19). Individuals in the age group over 60 years were the most completely immunized, at nearly 64 percent.

As of March 6, 20212 South Africa had administered a total of close to 32.03 million doses of the coronavirus (COVID-19) vaccine. The country faced a rough start to its vaccination program as health authorities claimed that the beta variant (B.1.351 or 501Y.V2) was resistant against the received AstraZeneca/Oxford immunizing. South Africa then started February 17 its phase one campaign, vaccinating health workers with Johnson and Johnson vaccines. Gauteng, the province with Johannesburg as capital, had the highest number of vaccinated individuals at 9.02 million. Western Cape and KwaZulu-Natal followed with five million and 4.93 million jabs being administered. These were the same regions with the highest number of COVID-19 cases registered in the country.

Around **** percent of Africa's population was fully vaccinated against the coronavirus (COVID-19) as of July 11, 2022. Over *** million vaccine doses have been administered on the continent since the beginning of the vaccination campaign in 2021. In general, Africa's vaccination rate is far lower than the global average.

Abstract

The COVID-19 Vaccine Survey (CVACS) is a South African national panel study of individuals initially unvaccinated against COVID-19. CVACS is implemented by the Southern Africa Labour and Development Research Unit (SALDRU) based at the University of Cape Town. The same respondents are interviewed twice, a few months apart, in 2021 and then 2022, to gather information about their attitudes, beliefs and intentions regarding COVID-19 vaccination. The purpose of CVACS is to collect high quality, timely, and relevant information on facilitators and barriers to COVID-19 vaccine uptake - including vaccine hesitancy and access constraints - to contribute to the development of data-driven campaigns and programmes to increase COVID-19 vaccination uptake in South Africa. In comparison to Survey 1, Survey 2 collected data on unvaccinated and vaccinated respondents. Final data files are: Unvaccinated (as was in S1) Vaccinated (New to S2) derived (As in S1) Link_File (New in S2 - this links the panel)

Geographic coverage

CVACS was not designed to be, and should not be used as a prevalence study. The data cannot be considered to be nationally representative of all unvaccinated individuals in South Africa.

Analysis unit

Households and individuals

Kind of data

Sample survey data [ssd]

Sampling procedure

CVACS Survey 1 was obtained from a stratified sample drawn from the GeoTerraImage (GTI) 2021 sampling frame (https://geoterraimage.com/), using individuals aged eighteen and older. The sample was primarily stratified across the following categories: province, population group, geographic area type (metro, non-metro urban, non-metro rural) and the neighbourhood lifestyle index (NLI), in groups of NLI 1-2, NLI 3-4, and NLI 5-10. Age categories defined according to the COVID-19 vaccination age groups (18-34, 35-49, 50-59, 60+), and gender were used as further explicit stratification variables. A credit bureau database was linked to this database at the enumeration area level, including individuals who had applied for credit, regardless of the outcome, and individuals who have had a credit check.

The CVACS Sample in Survey 2 included individuals from Survey 1 who were re-interviewed, who fell into two categories: vaccinated between Survey 1 and 2, or those remaining unvaccinated. In order to realise an unvaccinated sample of similar size to Survey 1, a top-up sample of unvaccinated individuals was interviewed. These individuals were drawn from the same sampling frame as Survey 1. Younger and female respondents were less likely to be re-interviewed in Survey 2. The full Survey 2 unvaccinated sample is more skewed to the younger age categories, due to higher vaccination rates among the elderly precluding many from inclusion into the study.

Mode of data collection

Computer Assisted Telephone Interview

Research instrument

Data was collected for Survey 2 with two questionnaires, one for vaccinated and one for unvaccinated respondents. CVACS used computer-assisted telephone interviews (CATI). The CVACS questionnaires were translated into all South African languages and interviews were conducted in the preferred language of the respondent. Most of the survey questions collected individual-level data, with some household level data also collected through the individual questionnaire.

As of November 17, 2022, Egypt had administered around 100 million coronavirus (COVID-19) vaccination doses, the highest number in Africa. Second in the ranking, Nigeria distributed ** million vaccines against the virus. South Africa, which accumulated the highest number of COVID-19 cases in the continent, carried out roughly ** million immunizations.

Africa still behind in the vaccination campaign

While *** doses of the COVID-19 vaccine have been administered per 100 people in the world, the vaccination rate in Africa is ** doses per 100 individuals. Besides being far slowest than the global average, the vaccination is marked by a striking divide between African countries. In February 2021, Africa started receiving vaccine supplies under the WHO-backed Covax facility. Additionally, some African nations purchased additional doses, while others were benefited from bilateral donations.

High acceptance of the coronavirus vaccine

While the COVID-19 vaccination still needs to gain pace in Africa, the majority of the continent’s population was willing to take a vaccine against the disease. According to a survey, nearly ** percent of Africans would get vaccinated, once the immunizing is considered safe and effective. However, one in four people believed a COVID-19 vaccine would be unsafe. Over *** million people in Africa were already infected by the virus since the beginning of the pandemic in March 2020.

Analysis of ‘COVID vaccination vs. mortality ’ provided by Analyst-2 (analyst-2.ai), based on source dataset retrieved from https://www.kaggle.com/sinakaraji/covid-vaccination-vs-death on 12 November 2021.

--- Dataset description provided by original source is as follows ---

Context

The COVID-19 outbreak has brought the whole planet to its knees.More over 4.5 million people have died since the writing of this notebook, and the only acceptable way out of the disaster is to vaccinate all parts of society. Despite the fact that the benefits of vaccination have been proved to the world many times, anti-vaccine groups are springing up all over the world. This data set was generated to investigate the impact of coronavirus vaccinations on coronavirus mortality.

Content

Data Collection

This dataset is a combination of the following three datasets:

1.https://www.kaggle.com/gpreda/covid-world-vaccination-progress

2.https://covid19.who.int/WHO-COVID-19-global-data.csv

3.https://www.kaggle.com/rsrishav/world-population

you can find more detail about this dataset by reading this notebook:

https://www.kaggle.com/sinakaraji/simple-linear-regression-covid-vaccination

Countries in this dataset:

--- Original source retains full ownership of the source dataset ---

South Africa ZA: Immunization: DPT: % of Children Aged 12-23 Months data was reported at 66.000 % in 2016. This records a decrease from the previous number of 75.000 % for 2015. South Africa ZA: Immunization: DPT: % of Children Aged 12-23 Months data is updated yearly, averaging 73.500 % from Dec 1983 (Median) to 2016, with 34 observations. The data reached an all-time high of 82.000 % in 2007 and a record low of 65.000 % in 2012. South Africa ZA: Immunization: DPT: % of Children Aged 12-23 Months data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s South Africa – Table ZA.World Bank: Health Statistics. Child immunization, DPT, measures the percentage of children ages 12-23 months who received DPT vaccinations before 12 months or at any time before the survey. A child is considered adequately immunized against diphtheria, pertussis (or whooping cough), and tetanus (DPT) after receiving three doses of vaccine.; ; WHO and UNICEF (http://www.who.int/immunization/monitoring_surveillance/en/).; Weighted average;

Countrywise vaccination status at the onset of the 3rd and 4th waves.

South Africa ZA: Immunization: Measles: % of Children Aged 12-23 Months data was reported at 60.000 % in 2017. This records a decrease from the previous number of 75.000 % for 2016. South Africa ZA: Immunization: Measles: % of Children Aged 12-23 Months data is updated yearly, averaging 70.000 % from Dec 1983 (Median) to 2017, with 35 observations. The data reached an all-time high of 85.000 % in 1993 and a record low of 60.000 % in 2017. South Africa ZA: Immunization: Measles: % of Children Aged 12-23 Months data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s South Africa – Table ZA.World Bank.WDI: Health Statistics. Child immunization, measles, measures the percentage of children ages 12-23 months who received the measles vaccination before 12 months or at any time before the survey. A child is considered adequately immunized against measles after receiving one dose of vaccine.; ; WHO and UNICEF (http://www.who.int/immunization/monitoring_surveillance/en/).; Weighted average;

Immunization against DPT of South Africa slumped by 7.06% from 85.0 % in 2022 to 79.0 % in 2023. Since the 2.38% rise in 2021, immunization against DPT dropped by 8.14% in 2023. Child immunization measures the percentage of children ages 12-23 months who received vaccinations before 12 months or at any time before the survey. A child is considered adequately immunized against diphtheria, pertussis (or whooping cough), and tetanus (DPT) after receiving three doses of vaccine.

South Africa ZA: Immunization: HepB3: % of One-Year-Old Children data was reported at 66.000 % in 2016. This records a decrease from the previous number of 75.000 % for 2015. South Africa ZA: Immunization: HepB3: % of One-Year-Old Children data is updated yearly, averaging 74.000 % from Dec 1997 (Median) to 2016, with 20 observations. The data reached an all-time high of 83.000 % in 2007 and a record low of 66.000 % in 2016. South Africa ZA: Immunization: HepB3: % of One-Year-Old Children data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s South Africa – Table ZA.World Bank: Health Statistics. Child immunization rate, hepatitis B is the percentage of children ages 12-23 months who received hepatitis B vaccinations before 12 months or at any time before the survey. A child is considered adequately immunized after three doses.; ; WHO and UNICEF (http://www.who.int/immunization/monitoring_surveillance/en/).; Weighted average;

Pooled COVID-19 vaccine acceptance rate stratified by sub-region and type of participants.

The COVID-19 Vaccine Market Report is Segmented by Technology Platform (mRNA Vaccines, Viral Vector Vaccines, and More), Valency (Monovalent Original, Bivalent Dual Strain, and More), End User (Government Immunization Programs, Hospitals & Clinics, Retail & Chain Pharmacies, and More), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, South America). The Market Forecasts are Provided in Terms of Value (USD).

Immunization, BCG (% of one-year-old children) in South Africa was reported at 79 % in 2023, according to the World Bank collection of development indicators, compiled from officially recognized sources. South Africa - Immunization, BCG (% of one-year-old children) - actual values, historical data, forecasts and projections were sourced from the World Bank on September of 2025.

Background: Rabies is a serious yet neglected public health threat in resource-limited communities in Africa, where the virus is maintained in populations of owned, free-roaming domestic dogs. Rabies elimination can be achieved through the mass vaccination of dogs, but maintaining the critical threshold of vaccination coverage for herd immunity in these populations is hampered by their rapid turnover. Knowledge of the population dynamics of free-roaming dog populations can inform effective planning and implementation of mass dog vaccination campaigns to control rabies. Methodology/Principal Findings: We implemented a health and demographic surveillance system in dogs that monitored the entire owned dog population within a defined geographic area in a community in Mpumalanga Province, South Africa. We quantified demographic rates over a 24-month period, from 1st January 2012 through 1st January 2014, and assessed their implications for rabies control by simulating the decline in vaccinat...

The global oral bordetella vaccine market size was valued at USD 138.8 million in 2022 and is projected to reach USD 261.7 million by 2033, exhibiting a CAGR of 6.7% during the forecast period. The increasing prevalence of whooping cough, coupled with rising awareness about vaccination benefits, is driving the market growth. Additionally, government initiatives and vaccination campaigns are expected to further contribute to market expansion. Key regional markets include North America, Europe, Asia Pacific, Middle East & Africa, and South America. North America held the largest market share in 2022, owing to high vaccination rates and established healthcare infrastructure. Asia Pacific is projected to register the fastest growth over the forecast period, due to growing disposable incomes, rising healthcare expenditure, and increasing awareness about bordetella vaccination. Key market players include Pfizer, Sanofi Pasteur, and GSK. Mergers and acquisitions, as well as strategic alliances, are common strategies adopted by these companies to expand their market presence and product portfolios. The oral bordetella vaccine market is projected to reach USD 1.5 billion by 2029, growing at a CAGR of 5.2% during the forecast period. The increasing incidence of whooping cough, the rising awareness of vaccination, and the growing demand for oral vaccines are driving the growth of the oral bordetella vaccine market.

Immunization, HepB3 (% of one-year-old children) in South Africa was reported at 79 % in 2023, according to the World Bank collection of development indicators, compiled from officially recognized sources. South Africa - Immunization, HepB3 (% of one-year-old children) - actual values, historical data, forecasts and projections were sourced from the World Bank on September of 2025.